Unveiling Long-Term Benefits of LEQEMBI® in Alzheimer's Treatment: Real-World Insights
In recent developments, Eisai Co., Ltd. and Biogen Inc. has presented groundbreaking findings from a comprehensive analysis highlighting the long-term treatment persistence of LEQEMBI® (lecanemab-irmb) among patients in the United States. This important announcement was made during the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026) held in Copenhagen, Denmark.
LEQEMBI® is an anti-amyloid-β (Aβ) protofibril antibody aimed at treating Alzheimer’s disease by targeting the toxic forms of amyloid-beta that contribute to cognitive decline. The data presented showed that an impressive 94% of participants who completed the initial 18-month treatment period opted to continue with maintenance therapy, demonstrating a strong preference for long-term treatment. This continuity is crucial, as studies suggest that patients with chronic conditions who adhere to their treatment regimens often experience significantly better clinical outcomes and higher satisfaction rates.
The analysis stemmed from a real-world retrospective observational study utilizing the PurpleLab® CLEAR Claims database. This extensive dataset compiles medical insurance claims from across the U.S., allowing researchers to evaluate patient experiences and treatment patterns over time. The study included a vast population of 10,763 individuals who had consistently engaged with healthcare and received IV treatments of lecanemab between early 2023 and late 2025.
Notable findings include the patient demographics of the respondents, with a mean age of 73.8 years and a majority being female (56.5%). Alongside the treatment, many participants reported common health issues such as dyslipidemia (42.2%) and hypertension (36.9%), which are often associated with Alzheimer's patients. The mean follow-up period lasted 350.9 days, with an average administration of 1.7 treatments per month, closely adhering to the recommended dosage schedule of every two weeks.
The results demonstrated the Kaplan–Meier method of tracking treatment persistence extended beyond the initial 18 months. Within a subgroup of patients who began treatment in 2023 and underwent continuous follow-up for 20 months, the findings illustrated that 78.4% remained on treatment at the 18-month mark. This percentage gradually decreased to 71.7% at 20 months and 67.3% at the 24-month point, underlining a commendable level of treatment perseverance in real-world clinical scenarios.
Previous studies have looked into treatment adherence, revealing potential contributing factors to patients discontinuing their medications, such as monitoring requirements and adverse side effects. Nevertheless, the adherence to lecanemab suggests that these challenges did not meaningfully deter patients in this recent analysis.
The collaborative effort between Eisai and Biogen, originating from a strategic alliance formed as early as 2014, continues to focus on unraveling new avenues for treating Alzheimer’s disease. With lecanemab receiving approval in 53 regions worldwide, including critical markets such as the U.S. and Europe, it signifies a pivotal leap in treatment strategies against Alzheimer’s dementia. Recent adjustments in treatment methodologies, such as the transition from intravenous to subcutaneous doses, highlight the response to patient preferences and the aim to enhance the overall treatment experience.
Furthermore, significant advancements have been made regarding clinical trials aimed at understanding Alzheimer’s disease better. The ongoing AHEAD 3-45 clinical study, dedicated to individuals with preclinical stages of Alzheimer’s, enlists the collaboration between Eisai and prominent clinical research groups, fostering innovations that could potentially yield new treatment methodologies.
The essential takeaway from this analysis is the evident patient satisfaction and willingness to continue using LEQEMBI®, showcasing its viability as a long-term treatment option for Alzheimer's patients. Both Eisai and Biogen are dedicated to advancing these findings into actionable healthcare solutions, benefitting individuals impacted by this debilitating condition. The future looks promising as they explore further enhancements and expansions in treatment offerings for patients with Alzheimer’s disease, aiming to not only improve clinical outcomes but enrich the quality of life for those affected by this challenging illness.
In conclusion, the persistence of treatment with LEQEMBI® serves as a beacon of hope for patients and caregivers alike, reaffirming the potential of continuous care in managing Alzheimer’s disease and its related challenges.
LEQEMBI® is an anti-amyloid-β (Aβ) protofibril antibody aimed at treating Alzheimer’s disease by targeting the toxic forms of amyloid-beta that contribute to cognitive decline. The data presented showed that an impressive 94% of participants who completed the initial 18-month treatment period opted to continue with maintenance therapy, demonstrating a strong preference for long-term treatment. This continuity is crucial, as studies suggest that patients with chronic conditions who adhere to their treatment regimens often experience significantly better clinical outcomes and higher satisfaction rates.
The analysis stemmed from a real-world retrospective observational study utilizing the PurpleLab® CLEAR Claims database. This extensive dataset compiles medical insurance claims from across the U.S., allowing researchers to evaluate patient experiences and treatment patterns over time. The study included a vast population of 10,763 individuals who had consistently engaged with healthcare and received IV treatments of lecanemab between early 2023 and late 2025.
Notable findings include the patient demographics of the respondents, with a mean age of 73.8 years and a majority being female (56.5%). Alongside the treatment, many participants reported common health issues such as dyslipidemia (42.2%) and hypertension (36.9%), which are often associated with Alzheimer's patients. The mean follow-up period lasted 350.9 days, with an average administration of 1.7 treatments per month, closely adhering to the recommended dosage schedule of every two weeks.
The results demonstrated the Kaplan–Meier method of tracking treatment persistence extended beyond the initial 18 months. Within a subgroup of patients who began treatment in 2023 and underwent continuous follow-up for 20 months, the findings illustrated that 78.4% remained on treatment at the 18-month mark. This percentage gradually decreased to 71.7% at 20 months and 67.3% at the 24-month point, underlining a commendable level of treatment perseverance in real-world clinical scenarios.
Previous studies have looked into treatment adherence, revealing potential contributing factors to patients discontinuing their medications, such as monitoring requirements and adverse side effects. Nevertheless, the adherence to lecanemab suggests that these challenges did not meaningfully deter patients in this recent analysis.
The collaborative effort between Eisai and Biogen, originating from a strategic alliance formed as early as 2014, continues to focus on unraveling new avenues for treating Alzheimer’s disease. With lecanemab receiving approval in 53 regions worldwide, including critical markets such as the U.S. and Europe, it signifies a pivotal leap in treatment strategies against Alzheimer’s dementia. Recent adjustments in treatment methodologies, such as the transition from intravenous to subcutaneous doses, highlight the response to patient preferences and the aim to enhance the overall treatment experience.
Furthermore, significant advancements have been made regarding clinical trials aimed at understanding Alzheimer’s disease better. The ongoing AHEAD 3-45 clinical study, dedicated to individuals with preclinical stages of Alzheimer’s, enlists the collaboration between Eisai and prominent clinical research groups, fostering innovations that could potentially yield new treatment methodologies.
The essential takeaway from this analysis is the evident patient satisfaction and willingness to continue using LEQEMBI®, showcasing its viability as a long-term treatment option for Alzheimer's patients. Both Eisai and Biogen are dedicated to advancing these findings into actionable healthcare solutions, benefitting individuals impacted by this debilitating condition. The future looks promising as they explore further enhancements and expansions in treatment offerings for patients with Alzheimer’s disease, aiming to not only improve clinical outcomes but enrich the quality of life for those affected by this challenging illness.
In conclusion, the persistence of treatment with LEQEMBI® serves as a beacon of hope for patients and caregivers alike, reaffirming the potential of continuous care in managing Alzheimer’s disease and its related challenges.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.